Literature DB >> 9156371

Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers.

W M Awni1, C Locke, L M Dube, J H Cavanaugh.   

Abstract

The diurnal variation in the pharmacokinetic parameters of zileuton were evaluated in 12 healthy male volunteers in a three-period study. Periods I and II constituted a balanced, randomized, crossover study in which a participant received a single dose of 600-mg zileuton either at 7 AM or 11 PM. In period III all participants received 600-mg doses four times daily for 5 days. The differences between the pharmacokinetics of single doses of zileuton administered at 7 AM and 11 PM were not statistically significant. Plasma concentration-time profiles of zileuton during the four daily dose intervals at steady state were also similar. Values for the pharmacokinetic parameters of zileuton after multiple doses were similar to those after single doses, with a minimal accumulation of the drug after multiple doses. Overall, there was little or no diurnal variation in the pharmacokinetic parameters of zileuton after single and multiple doses.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9156371     DOI: 10.1002/j.1552-4604.1997.tb04316.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  3 in total

Review 1.  Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.

Authors:  L M Dubé; L J Swanson; W Awni
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach.

Authors:  Tatiana A Karelina; Kirill V Zhudenkov; Oleg O Demin; Dmitry V Svetlichny; Balaji Agoram; David Fairman; Oleg V Demin
Journal:  BMC Syst Biol       Date:  2012-11-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.